Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,12845388,C(max),"Hemodialysis per se had no clinically meaningful effect on rofecoxib pharmacokinetics: plasma rofecoxib concentration-time curves were virtually superimposable when hemodialysis was initiated at 4 or 48 hours following rofecoxib dosing, although mean rofecoxib C(max) was 18% lower during the former (325 versus 395 ng/mL; P = 0.014).",Effects of renal insufficiency and hemodialysis on the pharmacokinetics of rofecoxib. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12845388/),[ng] / [ml],325,1136,DB00533,Rofecoxib
,12845388,C(max),"Hemodialysis per se had no clinically meaningful effect on rofecoxib pharmacokinetics: plasma rofecoxib concentration-time curves were virtually superimposable when hemodialysis was initiated at 4 or 48 hours following rofecoxib dosing, although mean rofecoxib C(max) was 18% lower during the former (325 versus 395 ng/mL; P = 0.014).",Effects of renal insufficiency and hemodialysis on the pharmacokinetics of rofecoxib. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12845388/),[ng] / [ml],395,1137,DB00533,Rofecoxib
,29864695,λmax,"A fast and efficient HPLC-UV method was developed, validated and applied for simultaneous determination of SOF and DCS in pharmaceutical formulations and biological fluids based on coupling liquid-liquid extraction with ultrasound and dual wavelength detection at λmax; 260 and 313 nm for SOF and DCS, respectively.",Simultaneous quantitation of two direct acting hepatitis C antivirals (sofosbuvir and daclatasvir) by an HPLC-UV method designated for their pharmacokinetic study in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29864695/),,260,7256,DB00533,Rofecoxib
,29864695,λmax,"A fast and efficient HPLC-UV method was developed, validated and applied for simultaneous determination of SOF and DCS in pharmaceutical formulations and biological fluids based on coupling liquid-liquid extraction with ultrasound and dual wavelength detection at λmax; 260 and 313 nm for SOF and DCS, respectively.",Simultaneous quantitation of two direct acting hepatitis C antivirals (sofosbuvir and daclatasvir) by an HPLC-UV method designated for their pharmacokinetic study in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29864695/),,313,7257,DB00533,Rofecoxib
,29864695,flow rate,Analytes were separated within 7 min on C18 analytical column with acetonitrile-10 mM acetate buffer of pH 5.0 at a flow rate of 1.0 mL min-1.,Simultaneous quantitation of two direct acting hepatitis C antivirals (sofosbuvir and daclatasvir) by an HPLC-UV method designated for their pharmacokinetic study in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29864695/),[ml] / [min],1.0,7258,DB00533,Rofecoxib
,29864695,detection limits,"The detection limits in spiked rabbit plasma were 0.20 and 0.19 μg mL-1 for SOF and DCS, respectively.",Simultaneous quantitation of two direct acting hepatitis C antivirals (sofosbuvir and daclatasvir) by an HPLC-UV method designated for their pharmacokinetic study in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29864695/),[μg] / [ml],0.20,7259,DB00533,Rofecoxib
,29864695,detection limits,"The detection limits in spiked rabbit plasma were 0.20 and 0.19 μg mL-1 for SOF and DCS, respectively.",Simultaneous quantitation of two direct acting hepatitis C antivirals (sofosbuvir and daclatasvir) by an HPLC-UV method designated for their pharmacokinetic study in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29864695/),[μg] / [ml],0.19,7260,DB00533,Rofecoxib
,21660124,total run time,Samples were injected in an online-SPE-LC-ESI-MS/MS setup allowing a total run time of only 126 s for a full gradient separation.,Development of an ultra fast online-solid phase extraction (SPE) liquid chromatography electrospray tandem mass spectrometry (LC-ESI-MS/MS) based approach for the determination of drugs in pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21660124/),s,126,17849,DB00533,Rofecoxib
,21660124,peak width (FWHM,DCF eluted at stable retention times (±0.33%) with narrow peak width (FWHM 3.3 ± 0.15 s).,Development of an ultra fast online-solid phase extraction (SPE) liquid chromatography electrospray tandem mass spectrometry (LC-ESI-MS/MS) based approach for the determination of drugs in pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21660124/),s,3.3,17850,DB00533,Rofecoxib
,21660124,limit of detection,"The method displays excellent analytical performance, with a limit of detection of 6 fmol on column, a linear range of over four orders of magnitude and a negligible carry over of 0.12 ± 0.03% for DCF.",Development of an ultra fast online-solid phase extraction (SPE) liquid chromatography electrospray tandem mass spectrometry (LC-ESI-MS/MS) based approach for the determination of drugs in pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21660124/),fmol,6,17851,DB00533,Rofecoxib
,21660124,carry over,"The method displays excellent analytical performance, with a limit of detection of 6 fmol on column, a linear range of over four orders of magnitude and a negligible carry over of 0.12 ± 0.03% for DCF.",Development of an ultra fast online-solid phase extraction (SPE) liquid chromatography electrospray tandem mass spectrometry (LC-ESI-MS/MS) based approach for the determination of drugs in pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21660124/),%,0.12,17852,DB00533,Rofecoxib
,10997947,plasma clearance,"After i.v. administration of [(14)C]rofecoxib to dogs, plasma clearance, volume of distribution at steady state, and elimination half-life values of rofecoxib were 3.6 ml/min/kg, 1.0 l/kg, and 2.6 h, respectively.","The absorption, distribution, metabolism and excretion of rofecoxib, a potent and selective cyclooxygenase-2 inhibitor, in rats and dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10997947/),[ml] / [kg·min],3.6,20527,DB00533,Rofecoxib
,10997947,volume of distribution at steady state,"After i.v. administration of [(14)C]rofecoxib to dogs, plasma clearance, volume of distribution at steady state, and elimination half-life values of rofecoxib were 3.6 ml/min/kg, 1.0 l/kg, and 2.6 h, respectively.","The absorption, distribution, metabolism and excretion of rofecoxib, a potent and selective cyclooxygenase-2 inhibitor, in rats and dogs. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10997947/),[l] / [kg],1.0,20528,DB00533,Rofecoxib
,10997947,elimination half-life,"After i.v. administration of [(14)C]rofecoxib to dogs, plasma clearance, volume of distribution at steady state, and elimination half-life values of rofecoxib were 3.6 ml/min/kg, 1.0 l/kg, and 2.6 h, respectively.","The absorption, distribution, metabolism and excretion of rofecoxib, a potent and selective cyclooxygenase-2 inhibitor, in rats and dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10997947/),h,2.6,20529,DB00533,Rofecoxib
,10997947,C(max),Oral absorption (5 mg/kg) was rapid in both species with C(max) occurring by 0.5 h (rats) and 1.5 h (dogs).,"The absorption, distribution, metabolism and excretion of rofecoxib, a potent and selective cyclooxygenase-2 inhibitor, in rats and dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10997947/),h,0.5,20530,DB00533,Rofecoxib
,10997947,C(max),Oral absorption (5 mg/kg) was rapid in both species with C(max) occurring by 0.5 h (rats) and 1.5 h (dogs).,"The absorption, distribution, metabolism and excretion of rofecoxib, a potent and selective cyclooxygenase-2 inhibitor, in rats and dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10997947/),h,1.5,20531,DB00533,Rofecoxib
,10997947,Bioavailability,Bioavailability in dogs was 26%.,"The absorption, distribution, metabolism and excretion of rofecoxib, a potent and selective cyclooxygenase-2 inhibitor, in rats and dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10997947/),%,26,20532,DB00533,Rofecoxib
,27811608,Cmax,"Cmax averaged 582 ± 129 ng/mL, with a median tmax of 4.0 hours.",Pharmacokinetics of Rofecoxib in Children With Sickle Cell Hemoglobinopathy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27811608/),[ng] / [ml],582,55906,DB00533,Rofecoxib
,27811608,tmax,"Cmax averaged 582 ± 129 ng/mL, with a median tmax of 4.0 hours.",Pharmacokinetics of Rofecoxib in Children With Sickle Cell Hemoglobinopathy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27811608/),h,4.0,55907,DB00533,Rofecoxib
,27811608,Cl/F,"In the remaining six subjects, Cl/F averaged 1.34 ± 0.32 mL/min/kg, with a t½ of 14.8 ± 4.5 hours.",Pharmacokinetics of Rofecoxib in Children With Sickle Cell Hemoglobinopathy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27811608/),[ml] / [kg·min],1.34,55908,DB00533,Rofecoxib
,27811608,t½,"In the remaining six subjects, Cl/F averaged 1.34 ± 0.32 mL/min/kg, with a t½ of 14.8 ± 4.5 hours.",Pharmacokinetics of Rofecoxib in Children With Sickle Cell Hemoglobinopathy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27811608/),h,14.8,55909,DB00533,Rofecoxib
,23773132,Peak plasma concentrations (Cmax),The Peak plasma concentrations (Cmax) of 8.34 ng/mL at tmax of 4 h and Cmax of 76.84 ng/mL at tmax of 3 h were observed for RFB and solid mixture respectively.,Bioavailability and pharmacokinetic studies of rofecoxib solid dispersion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23773132/),[ng] / [ml],8.34,56246,DB00533,Rofecoxib
,23773132,tmax,The Peak plasma concentrations (Cmax) of 8.34 ng/mL at tmax of 4 h and Cmax of 76.84 ng/mL at tmax of 3 h were observed for RFB and solid mixture respectively.,Bioavailability and pharmacokinetic studies of rofecoxib solid dispersion. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23773132/),h,4,56247,DB00533,Rofecoxib
,23773132,Cmax,The Peak plasma concentrations (Cmax) of 8.34 ng/mL at tmax of 4 h and Cmax of 76.84 ng/mL at tmax of 3 h were observed for RFB and solid mixture respectively.,Bioavailability and pharmacokinetic studies of rofecoxib solid dispersion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23773132/),[ng] / [ml],76.84,56248,DB00533,Rofecoxib
,23773132,tmax,The Peak plasma concentrations (Cmax) of 8.34 ng/mL at tmax of 4 h and Cmax of 76.84 ng/mL at tmax of 3 h were observed for RFB and solid mixture respectively.,Bioavailability and pharmacokinetic studies of rofecoxib solid dispersion. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23773132/),h,3,56249,DB00533,Rofecoxib
,14761182,ED(50),"In case of 20b, a representative compound for sulfonamide derivatives, a potent antiinflammatory ED(50) of 0.1 mg kg(-1) day(-1) was observed against adjuvant-induced arthritis by a preventive model, positioning 20b as one of the most potent COX-2 inhibitors ever reported.","In vitro structure-activity relationship and in vivo studies for a novel class of cyclooxygenase-2 inhibitors: 5-aryl-2,2-dialkyl-4-phenyl-3(2H)furanone derivatives. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14761182/),[mg] / [day·kg],0.1,63492,DB00533,Rofecoxib
,14761182,ED(50),"Furthermore, 20b showed strong analgesic activity as indicated by its ED(50) of 0.25 mg/kg against carrageenan-induced thermal hyperalgesia in the Sprague-Dawley rat.","In vitro structure-activity relationship and in vivo studies for a novel class of cyclooxygenase-2 inhibitors: 5-aryl-2,2-dialkyl-4-phenyl-3(2H)furanone derivatives. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14761182/),[mg] / [kg],0.25,63493,DB00533,Rofecoxib
,17435173,IC50,"In vitro, metabolites elicited no substantial COX-1/COX-2 selectivity with MAA (IC50=2.55 micromol/L for COX-1; IC50=4.65 micromol/L for COX-2), being approximately 8.2- or 9-fold more potent than AA.",Dipyrone elicits substantial inhibition of peripheral cyclooxygenases in humans: new insights into the pharmacology of an old analgesic. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17435173/),[μM] / [l],2.55,76643,DB00533,Rofecoxib
,17435173,IC50,"In vitro, metabolites elicited no substantial COX-1/COX-2 selectivity with MAA (IC50=2.55 micromol/L for COX-1; IC50=4.65 micromol/L for COX-2), being approximately 8.2- or 9-fold more potent than AA.",Dipyrone elicits substantial inhibition of peripheral cyclooxygenases in humans: new insights into the pharmacology of an old analgesic. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17435173/),[μM] / [l],4.65,76644,DB00533,Rofecoxib
,17435173,IC50,COX inhibition correlated with MAA plasma levels (ex vivo IC50 values of 1.03 micromol/L [COX-1] and 0.87 micromol/L [COX-2]).,Dipyrone elicits substantial inhibition of peripheral cyclooxygenases in humans: new insights into the pharmacology of an old analgesic. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17435173/),[μM] / [l],1.03,76645,DB00533,Rofecoxib
,17435173,IC50,COX inhibition correlated with MAA plasma levels (ex vivo IC50 values of 1.03 micromol/L [COX-1] and 0.87 micromol/L [COX-2]).,Dipyrone elicits substantial inhibition of peripheral cyclooxygenases in humans: new insights into the pharmacology of an old analgesic. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17435173/),[μM] / [l],0.87,76646,DB00533,Rofecoxib
,17435173,Maximal inhibitions,"Maximal inhibitions of COX-1 and COX-2 were 94% and 87% (500 mg), 97% and 94% (1000 mg).",Dipyrone elicits substantial inhibition of peripheral cyclooxygenases in humans: new insights into the pharmacology of an old analgesic. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17435173/),%,94,76647,DB00533,Rofecoxib
,17435173,Maximal inhibitions,"Maximal inhibitions of COX-1 and COX-2 were 94% and 87% (500 mg), 97% and 94% (1000 mg).",Dipyrone elicits substantial inhibition of peripheral cyclooxygenases in humans: new insights into the pharmacology of an old analgesic. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17435173/),%,87,76648,DB00533,Rofecoxib
,17435173,Maximal inhibitions,"Maximal inhibitions of COX-1 and COX-2 were 94% and 87% (500 mg), 97% and 94% (1000 mg).",Dipyrone elicits substantial inhibition of peripheral cyclooxygenases in humans: new insights into the pharmacology of an old analgesic. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17435173/),%,97,76649,DB00533,Rofecoxib
,11522069,retention time,The retention time of rofecoxib was 1.2 min.,Selective and rapid liquid chromatography-mass spectrometry method for the quantification of rofecoxib in pharmacokinetic studies with humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11522069/),min,1.2,91753,DB00533,Rofecoxib
,11522069,tmax,"The pharmacokinetic characteristics (mean+/-SD) were tmax: 2.4+/-1.0 h, Cmax: 147+/-34 microg/l, AUCinfinity: 2038+/-581 microg h/l and t 1/2: 11.3+/-2.1 h.",Selective and rapid liquid chromatography-mass spectrometry method for the quantification of rofecoxib in pharmacokinetic studies with humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11522069/),h,2.4,91754,DB00533,Rofecoxib
,11522069,Cmax,"The pharmacokinetic characteristics (mean+/-SD) were tmax: 2.4+/-1.0 h, Cmax: 147+/-34 microg/l, AUCinfinity: 2038+/-581 microg h/l and t 1/2: 11.3+/-2.1 h.",Selective and rapid liquid chromatography-mass spectrometry method for the quantification of rofecoxib in pharmacokinetic studies with humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11522069/),[μg] / [l],147,91755,DB00533,Rofecoxib
,11522069,AUCinfinity,"The pharmacokinetic characteristics (mean+/-SD) were tmax: 2.4+/-1.0 h, Cmax: 147+/-34 microg/l, AUCinfinity: 2038+/-581 microg h/l and t 1/2: 11.3+/-2.1 h.",Selective and rapid liquid chromatography-mass spectrometry method for the quantification of rofecoxib in pharmacokinetic studies with humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11522069/),[h·μg] / [l],2038,91756,DB00533,Rofecoxib
,11522069,t 1/2,"The pharmacokinetic characteristics (mean+/-SD) were tmax: 2.4+/-1.0 h, Cmax: 147+/-34 microg/l, AUCinfinity: 2038+/-581 microg h/l and t 1/2: 11.3+/-2.1 h.",Selective and rapid liquid chromatography-mass spectrometry method for the quantification of rofecoxib in pharmacokinetic studies with humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11522069/),h,11.3,91757,DB00533,Rofecoxib
,17920584,IC(50),"CS-706 selectively inhibited COX-2 in a human whole blood assay with an IC(50) of 0.31 microM, compared with an IC(50) of 2.2 microM for COX-1.","Preclinical pharmacology profile of CS-706, a novel cyclooxygenase-2 selective inhibitor, with potent antinociceptive and anti-inflammatory effects. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17920584/),μM,0.31,94872,DB00533,Rofecoxib
,17920584,IC(50),"CS-706 selectively inhibited COX-2 in a human whole blood assay with an IC(50) of 0.31 microM, compared with an IC(50) of 2.2 microM for COX-1.","Preclinical pharmacology profile of CS-706, a novel cyclooxygenase-2 selective inhibitor, with potent antinociceptive and anti-inflammatory effects. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17920584/),μM,2.2,94873,DB00533,Rofecoxib
,17920584,ID(50),"In an adjuvant-induced arthritic model in rats, CS-706 suppressed foot swelling prophylactically with an ID(50) of 0.10 mg/kg/day, and decreased foot swelling in the established arthritis therapeutically in a dose range of 0.040 to 1.0 mg/kg/day.","Preclinical pharmacology profile of CS-706, a novel cyclooxygenase-2 selective inhibitor, with potent antinociceptive and anti-inflammatory effects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17920584/),[mg] / [d·kg],0.10,94874,DB00533,Rofecoxib
,15454838,Cmax,"Cmax averaged 582 +/- 129 ng/mL, with a median tmax of 4.0 hours.",Pharmacokinetics of rofecoxib in children with sickle cell hemoglobinopathy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15454838/),[ng] / [ml],582,101588,DB00533,Rofecoxib
,15454838,tmax,"Cmax averaged 582 +/- 129 ng/mL, with a median tmax of 4.0 hours.",Pharmacokinetics of rofecoxib in children with sickle cell hemoglobinopathy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15454838/),h,4.0,101589,DB00533,Rofecoxib
,15454838,Cl/F,"In the remaining six subjects, Cl/F averaged 1.34 +/- 0.32 mL/min/kg, with a t1/2 of 14.8 +/- 4.5 hours.",Pharmacokinetics of rofecoxib in children with sickle cell hemoglobinopathy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15454838/),[ml] / [kg·min],1.34,101590,DB00533,Rofecoxib
,15454838,t1/2,"In the remaining six subjects, Cl/F averaged 1.34 +/- 0.32 mL/min/kg, with a t1/2 of 14.8 +/- 4.5 hours.",Pharmacokinetics of rofecoxib in children with sickle cell hemoglobinopathy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15454838/),h,14.8,101591,DB00533,Rofecoxib
,10877012,Elimination half-life,Elimination half-life ranged from 9.9 h to 17.5 h after multiple dosing with an accumulation ratio close to 2 for all doses.,"Pharmacokinetics, COX-2 specificity, and tolerability of supratherapeutic doses of rofecoxib in humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10877012/),h,9.9,106237,DB00533,Rofecoxib
,10877012,Elimination half-life,Elimination half-life ranged from 9.9 h to 17.5 h after multiple dosing with an accumulation ratio close to 2 for all doses.,"Pharmacokinetics, COX-2 specificity, and tolerability of supratherapeutic doses of rofecoxib in humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10877012/),h,17.5,106238,DB00533,Rofecoxib
,10877012,accumulation ratio,Elimination half-life ranged from 9.9 h to 17.5 h after multiple dosing with an accumulation ratio close to 2 for all doses.,"Pharmacokinetics, COX-2 specificity, and tolerability of supratherapeutic doses of rofecoxib in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10877012/),,2,106239,DB00533,Rofecoxib
,11816012,retention time,The retention time of celecoxib was 2.3 min.,Investigation of the pharmacokinetics of celecoxib by liquid chromatography-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11816012/),min,2.3,112197,DB00533,Rofecoxib
,11816012,t(max),"Pharmacokinetic characteristics (mean +/- SD) of extensive metabolizers (EM) were t(max) 2.9+/-1.2h, c(max) 842+/-280 microg/L, AUC(infinity) 6246+/-2147 microg h/L and t(1/2) 7.8+/-2.7h.",Investigation of the pharmacokinetics of celecoxib by liquid chromatography-mass spectrometry. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11816012/),h,2.9,112198,DB00533,Rofecoxib
,11816012,c(max),"Pharmacokinetic characteristics (mean +/- SD) of extensive metabolizers (EM) were t(max) 2.9+/-1.2h, c(max) 842+/-280 microg/L, AUC(infinity) 6246+/-2147 microg h/L and t(1/2) 7.8+/-2.7h.",Investigation of the pharmacokinetics of celecoxib by liquid chromatography-mass spectrometry. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11816012/),[μg] / [l],842,112199,DB00533,Rofecoxib
,11816012,AUC(infinity),"Pharmacokinetic characteristics (mean +/- SD) of extensive metabolizers (EM) were t(max) 2.9+/-1.2h, c(max) 842+/-280 microg/L, AUC(infinity) 6246+/-2147 microg h/L and t(1/2) 7.8+/-2.7h.",Investigation of the pharmacokinetics of celecoxib by liquid chromatography-mass spectrometry. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11816012/),[h·μg] / [l],6246,112200,DB00533,Rofecoxib
,11816012,t(1/2),"Pharmacokinetic characteristics (mean +/- SD) of extensive metabolizers (EM) were t(max) 2.9+/-1.2h, c(max) 842+/-280 microg/L, AUC(infinity) 6246+/-2147 microg h/L and t(1/2) 7.8+/-2.7h.",Investigation of the pharmacokinetics of celecoxib by liquid chromatography-mass spectrometry. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11816012/),h,7.8,112201,DB00533,Rofecoxib
,11816012,area under the curve (AUC(infinity)),The area under the curve (AUC(infinity)) for the PM was 12561 microg h/L.,Investigation of the pharmacokinetics of celecoxib by liquid chromatography-mass spectrometry. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11816012/),[h·μg] / [l],12561,112202,DB00533,Rofecoxib
,11816012,half life,"However, we found no noticeable increase in half life in the PM (11.5 h) after a single dose of celecoxib.",Investigation of the pharmacokinetics of celecoxib by liquid chromatography-mass spectrometry. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11816012/),h,11.5,112203,DB00533,Rofecoxib
,16176646,flow rate,"UV detection is performed at 254 nm, and the flow rate is maintained at 1.0 mL/min.",Simultaneous determination of rofecoxib and celecoxib in human plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16176646/),[ml] / [min],1.0,113197,DB00533,Rofecoxib
,11863283,flow-rate,"After liquid-liquid extraction of I, II, and internal standard (III) from plasma, the analytes were chromatographed on a narrow bore (100 mm x 3.0 mm) C18 analytical column, with mobile phase consisting of acetonitrile-water (1:1, v/v) at a flow-rate of 0.5 ml/min.",High-performance liquid chromatographic-tandem mass spectrometric evaluation and determination of stable isotope labeled analogs of rofecoxib in human plasma samples from oral bioavailability studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11863283/),[ml] / [min],0.5,118169,DB00533,Rofecoxib
,15900289,maximal,"Urinary sodium excretion was reduced in all active treatment groups (maximal reduction of approximately 11 mmol/h during normal sodium intake, P < .05 versus placebo for all groups).",Renal effects of the cyclooxygenase-inhibiting nitric oxide donator AZD3582 compared with rofecoxib and naproxen during normal and low sodium intake. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15900289/),,11,120422,DB00533,Rofecoxib
,15900289,maximal reduction,"In sodium-depleted subjects, the mean (SD) maximal reduction in GFR during 0 to 6 hours for 750 mg AZD3582, 1500 mg AZD3582, 50 mg rofecoxib, and 500 mg naproxen was 28.1 mL/min (13.5 mL/min), 33.7 mL/min (23.3 mL/min), 25.2 mL/min (29.2 mL/min), and 41.7 mL/min (30.7 mL/min), respectively, with a statistically significant difference between 500 mg naproxen and placebo.",Renal effects of the cyclooxygenase-inhibiting nitric oxide donator AZD3582 compared with rofecoxib and naproxen during normal and low sodium intake. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15900289/),[ml] / [min],28.1,120423,DB00533,Rofecoxib
,15900289,maximal reduction,"In sodium-depleted subjects, the mean (SD) maximal reduction in GFR during 0 to 6 hours for 750 mg AZD3582, 1500 mg AZD3582, 50 mg rofecoxib, and 500 mg naproxen was 28.1 mL/min (13.5 mL/min), 33.7 mL/min (23.3 mL/min), 25.2 mL/min (29.2 mL/min), and 41.7 mL/min (30.7 mL/min), respectively, with a statistically significant difference between 500 mg naproxen and placebo.",Renal effects of the cyclooxygenase-inhibiting nitric oxide donator AZD3582 compared with rofecoxib and naproxen during normal and low sodium intake. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15900289/),[ml] / [min],33.7,120424,DB00533,Rofecoxib
,15900289,maximal reduction,"In sodium-depleted subjects, the mean (SD) maximal reduction in GFR during 0 to 6 hours for 750 mg AZD3582, 1500 mg AZD3582, 50 mg rofecoxib, and 500 mg naproxen was 28.1 mL/min (13.5 mL/min), 33.7 mL/min (23.3 mL/min), 25.2 mL/min (29.2 mL/min), and 41.7 mL/min (30.7 mL/min), respectively, with a statistically significant difference between 500 mg naproxen and placebo.",Renal effects of the cyclooxygenase-inhibiting nitric oxide donator AZD3582 compared with rofecoxib and naproxen during normal and low sodium intake. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15900289/),[ml] / [min],25.2,120425,DB00533,Rofecoxib
,15900289,maximal reduction,"In sodium-depleted subjects, the mean (SD) maximal reduction in GFR during 0 to 6 hours for 750 mg AZD3582, 1500 mg AZD3582, 50 mg rofecoxib, and 500 mg naproxen was 28.1 mL/min (13.5 mL/min), 33.7 mL/min (23.3 mL/min), 25.2 mL/min (29.2 mL/min), and 41.7 mL/min (30.7 mL/min), respectively, with a statistically significant difference between 500 mg naproxen and placebo.",Renal effects of the cyclooxygenase-inhibiting nitric oxide donator AZD3582 compared with rofecoxib and naproxen during normal and low sodium intake. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15900289/),[ml] / [min],41.7,120426,DB00533,Rofecoxib
,16724516,IC50,"BDD-11602 and rofecoxib inhibited COX-2-derived PGE(2) synthesis with IC50 values of 173 nmol/l and 169 nmol/l, respectively.",Enhanced plasma concentration by selective deuteration of rofecoxib in rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16724516/),[nM] / [l],173,120990,DB00533,Rofecoxib
,16724516,IC50,"BDD-11602 and rofecoxib inhibited COX-2-derived PGE(2) synthesis with IC50 values of 173 nmol/l and 169 nmol/l, respectively.",Enhanced plasma concentration by selective deuteration of rofecoxib in rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16724516/),[nM] / [l],169,120991,DB00533,Rofecoxib
above,16724516,IC50,IC50 values for inhibition of human platelet COX-1 were estimated to be above 1 micromol/l for both compounds.,Enhanced plasma concentration by selective deuteration of rofecoxib in rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16724516/),[μM] / [l],1,120992,DB00533,Rofecoxib
,15845677,AUC(CSF)/AUC(plasma) ratio,"After nine consecutive daily doses of rofecoxib, the AUC(CSF)/AUC(plasma) ratio was 0.159.",Cerebrospinal fluid and plasma pharmacokinetics of the cyclooxygenase 2 inhibitor rofecoxib in humans: single and multiple oral drug administration. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15845677/),,0.159,144955,DB00533,Rofecoxib
,11144988,tmax,The digoxin median tmax was 0.5 hours for both treatments.,Effect of rofecoxib on the pharmacokinetics of digoxin in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11144988/),h,0.5,151253,DB00533,Rofecoxib
,11144988,elimination half-life,"The harmonic mean elimination half-life was 45.7 and 43.4 hours for rofecoxib + digoxin and placebo + digoxin treatments, respectively.",Effect of rofecoxib on the pharmacokinetics of digoxin in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11144988/),h,45.7,151254,DB00533,Rofecoxib
,11144988,elimination half-life,"The harmonic mean elimination half-life was 45.7 and 43.4 hours for rofecoxib + digoxin and placebo + digoxin treatments, respectively.",Effect of rofecoxib on the pharmacokinetics of digoxin in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11144988/),h,43.4,151255,DB00533,Rofecoxib
,11144988,cumulative urinary excretion,"The mean (SD) cumulative urinary excretion of immunoreactive digoxin after concurrent treatment with rofecoxib or placebo was 228.2 (+/- 30.8) and 235.1 (+/- 39.1) micrograms/120 hours, respectively.",Effect of rofecoxib on the pharmacokinetics of digoxin in healthy volunteers. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11144988/),[μg] / [120·h],228.2,151256,DB00533,Rofecoxib
,11144988,cumulative urinary excretion,"The mean (SD) cumulative urinary excretion of immunoreactive digoxin after concurrent treatment with rofecoxib or placebo was 228.2 (+/- 30.8) and 235.1 (+/- 39.1) micrograms/120 hours, respectively.",Effect of rofecoxib on the pharmacokinetics of digoxin in healthy volunteers. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11144988/),[μg] / [120·h],235.1,151257,DB00533,Rofecoxib
,15881813,retention time,The retention time of I.S and sildenafil were 5.5 minutes and 7.2 minutes respectively.,Bioequivalence study of sildenafil citrate tablets in healthy human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15881813/),min,5.5,153718,DB00533,Rofecoxib
,15881813,retention time,The retention time of I.S and sildenafil were 5.5 minutes and 7.2 minutes respectively.,Bioequivalence study of sildenafil citrate tablets in healthy human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15881813/),min,7.2,153719,DB00533,Rofecoxib
,15881813,extraction efficiency,The extraction efficiency from plasma varied from 79.69% to 81.13 %.,Bioequivalence study of sildenafil citrate tablets in healthy human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15881813/),%,79.69,153720,DB00533,Rofecoxib
,15881813,extraction efficiency,The extraction efficiency from plasma varied from 79.69% to 81.13 %.,Bioequivalence study of sildenafil citrate tablets in healthy human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15881813/),%,81.13,153721,DB00533,Rofecoxib
,15881813,minimum quantifiable concentration,The minimum quantifiable concentration was set at 10 ng/ml.,Bioequivalence study of sildenafil citrate tablets in healthy human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15881813/),[ng] / [ml],10,153722,DB00533,Rofecoxib
,18197403,K(i) (inhibitor constant),Celecoxib was found to be a moderately potent competitive inhibitor of CYP1A2 in vitro with a K(i) (inhibitor constant) of 25.4 microM.,Celecoxib is a CYP1A2 inhibitor in vitro but not in vivo. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18197403/),μM,25.4,155529,DB00533,Rofecoxib
,15071803,retention time,"The retention time of rofecoxib after recovery from plasma, was 8.9 minutes.",High performance liquid chromatographic determination of cox-2 inhibitor rofecoxib in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15071803/),min,8.9,155979,DB00533,Rofecoxib
,15071803,extraction efficiency,The extraction efficiency from plasma varied from 93.95-99.58%.,High performance liquid chromatographic determination of cox-2 inhibitor rofecoxib in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15071803/),%,93.95-99.58,155980,DB00533,Rofecoxib
,15071803,minimum quantifiable concentration,The minimum quantifiable concentration was set at 50 ng/ml (% CV < 10%).,High performance liquid chromatographic determination of cox-2 inhibitor rofecoxib in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15071803/),[ng] / [ml],50,155981,DB00533,Rofecoxib
,15071803,Cmax,"The pharmacokinetic parameters were Cmax = 318.58 +/- 30.65 ng/ml at tmax = 2.66 +/- 0.25 hours, AUC0-t = 4007.88 +/- 438.32 ng hour/ml, AUC0-yen = 5454.66 +/- 822.29 ng hour/ml, Kel = 0.0433 +/- 0.0067/hour, and t1/2 = 16.36 +/- 2.89 hours.",High performance liquid chromatographic determination of cox-2 inhibitor rofecoxib in human plasma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15071803/),[ng] / [ml],318.58,155982,DB00533,Rofecoxib
,15071803,tmax,"The pharmacokinetic parameters were Cmax = 318.58 +/- 30.65 ng/ml at tmax = 2.66 +/- 0.25 hours, AUC0-t = 4007.88 +/- 438.32 ng hour/ml, AUC0-yen = 5454.66 +/- 822.29 ng hour/ml, Kel = 0.0433 +/- 0.0067/hour, and t1/2 = 16.36 +/- 2.89 hours.",High performance liquid chromatographic determination of cox-2 inhibitor rofecoxib in human plasma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15071803/),h,2.66,155983,DB00533,Rofecoxib
,15071803,AUC0-t,"The pharmacokinetic parameters were Cmax = 318.58 +/- 30.65 ng/ml at tmax = 2.66 +/- 0.25 hours, AUC0-t = 4007.88 +/- 438.32 ng hour/ml, AUC0-yen = 5454.66 +/- 822.29 ng hour/ml, Kel = 0.0433 +/- 0.0067/hour, and t1/2 = 16.36 +/- 2.89 hours.",High performance liquid chromatographic determination of cox-2 inhibitor rofecoxib in human plasma. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15071803/),[h·ng] / [ml],4007.88,155984,DB00533,Rofecoxib
,15071803,AUC0-yen,"The pharmacokinetic parameters were Cmax = 318.58 +/- 30.65 ng/ml at tmax = 2.66 +/- 0.25 hours, AUC0-t = 4007.88 +/- 438.32 ng hour/ml, AUC0-yen = 5454.66 +/- 822.29 ng hour/ml, Kel = 0.0433 +/- 0.0067/hour, and t1/2 = 16.36 +/- 2.89 hours.",High performance liquid chromatographic determination of cox-2 inhibitor rofecoxib in human plasma. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15071803/),[h·ng] / [ml],5454.66,155985,DB00533,Rofecoxib
,15071803,Kel,"The pharmacokinetic parameters were Cmax = 318.58 +/- 30.65 ng/ml at tmax = 2.66 +/- 0.25 hours, AUC0-t = 4007.88 +/- 438.32 ng hour/ml, AUC0-yen = 5454.66 +/- 822.29 ng hour/ml, Kel = 0.0433 +/- 0.0067/hour, and t1/2 = 16.36 +/- 2.89 hours.",High performance liquid chromatographic determination of cox-2 inhibitor rofecoxib in human plasma. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15071803/),1/[h],0.0433,155986,DB00533,Rofecoxib
,15071803,t1/2,"The pharmacokinetic parameters were Cmax = 318.58 +/- 30.65 ng/ml at tmax = 2.66 +/- 0.25 hours, AUC0-t = 4007.88 +/- 438.32 ng hour/ml, AUC0-yen = 5454.66 +/- 822.29 ng hour/ml, Kel = 0.0433 +/- 0.0067/hour, and t1/2 = 16.36 +/- 2.89 hours.",High performance liquid chromatographic determination of cox-2 inhibitor rofecoxib in human plasma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15071803/),h,16.36,155987,DB00533,Rofecoxib
,12891223,area under the plasma concentration-time curve,"Celecoxib significantly increased the area under the plasma concentration-time curve of metoprolol from 271 to 414 micro g. h/L (64% +/- 57%, P <.001) and by more than 200% in 1 volunteer.",Celecoxib inhibits metabolism of cytochrome P450 2D6 substrate metoprolol in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12891223/),[h·μg] / [l],271 to 414,161598,DB00533,Rofecoxib
,12891223,area under the plasma concentration-time curve from 0 to 24 hours,"After administration of celecoxib, the area under the plasma concentration-time curve from 0 to 24 hours of alpha-hydroxymetoprolol decreased significantly from 474 to 387 micro g. h/L (P <.01).",Celecoxib inhibits metabolism of cytochrome P450 2D6 substrate metoprolol in humans. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12891223/),[h·μg] / [l],474,161599,DB00533,Rofecoxib
,12891223,area under the plasma concentration-time curve from 0 to 24 hours,"After administration of celecoxib, the area under the plasma concentration-time curve from 0 to 24 hours of alpha-hydroxymetoprolol decreased significantly from 474 to 387 micro g. h/L (P <.01).",Celecoxib inhibits metabolism of cytochrome P450 2D6 substrate metoprolol in humans. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12891223/),[h·μg] / [l],38,161600,DB00533,Rofecoxib
,16995327,area under the plasma concentration-time curve,No effect of valdecoxib (20 mg/d) or rofecoxib (25 mg/d) were detected on the area under the plasma concentration-time curve of metoprolol (323 +/- 333 to 324 +/- 296 or 309 +/- 256 microg x h/l) or at a higher dose.,Valdecoxib does not interfere with the CYP2D6 substrate metoprolol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16995327/),[h·μg] / [l],323,164280,DB00533,Rofecoxib
,16995327,area under the plasma concentration-time curve,No effect of valdecoxib (20 mg/d) or rofecoxib (25 mg/d) were detected on the area under the plasma concentration-time curve of metoprolol (323 +/- 333 to 324 +/- 296 or 309 +/- 256 microg x h/l) or at a higher dose.,Valdecoxib does not interfere with the CYP2D6 substrate metoprolol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16995327/),[h·μg] / [l],324,164281,DB00533,Rofecoxib
,16995327,area under the plasma concentration-time curve,No effect of valdecoxib (20 mg/d) or rofecoxib (25 mg/d) were detected on the area under the plasma concentration-time curve of metoprolol (323 +/- 333 to 324 +/- 296 or 309 +/- 256 microg x h/l) or at a higher dose.,Valdecoxib does not interfere with the CYP2D6 substrate metoprolol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16995327/),[h·μg] / [l],309,164282,DB00533,Rofecoxib
>,11177649,extraction efficiency,The extraction efficiency was >87%.,High performance liquid chromatographic determination of cyclooxygenase II inhibitor rofecoxib in rat and human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11177649/),%,87,264655,DB00533,Rofecoxib
,11177649,minimum quantifiable concentration,The minimum quantifiable concentration was set at 10 ng/mL (correlation coefficient of <10%).,High performance liquid chromatographic determination of cyclooxygenase II inhibitor rofecoxib in rat and human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11177649/),[ng] / [ml],10,264656,DB00533,Rofecoxib
,15497671,Cmax,"The mean Cmax were 192.07 ng/mL and 187.35 ng/mL, while the mean AUC0-t were 3613.84 ng x h/mL and 3501.56 ng x h/mL for the test and reference formulations, respectively.",Bioequivalence study of rofecoxib tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15497671/),[ng] / [ml],192.07,269807,DB00533,Rofecoxib
,15497671,Cmax,"The mean Cmax were 192.07 ng/mL and 187.35 ng/mL, while the mean AUC0-t were 3613.84 ng x h/mL and 3501.56 ng x h/mL for the test and reference formulations, respectively.",Bioequivalence study of rofecoxib tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15497671/),[ng] / [ml],187.35,269808,DB00533,Rofecoxib
,15497671,AUC0-t,"The mean Cmax were 192.07 ng/mL and 187.35 ng/mL, while the mean AUC0-t were 3613.84 ng x h/mL and 3501.56 ng x h/mL for the test and reference formulations, respectively.",Bioequivalence study of rofecoxib tablets. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15497671/),[h·ng] / [ml],3613.84,269809,DB00533,Rofecoxib
,15497671,AUC0-t,"The mean Cmax were 192.07 ng/mL and 187.35 ng/mL, while the mean AUC0-t were 3613.84 ng x h/mL and 3501.56 ng x h/mL for the test and reference formulations, respectively.",Bioequivalence study of rofecoxib tablets. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15497671/),[h·ng] / [ml],3501.56,269810,DB00533,Rofecoxib
,15497671,tmax,The median tmax was 3.75 h for the test tablet and 4.00 h for the reference formulation.,Bioequivalence study of rofecoxib tablets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15497671/),h,3.75,269811,DB00533,Rofecoxib
,15497671,tmax,The median tmax was 3.75 h for the test tablet and 4.00 h for the reference formulation.,Bioequivalence study of rofecoxib tablets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15497671/),h,4.00,269812,DB00533,Rofecoxib
,15497671,t(1/2 el),"The mean t(1/2 el) was 10.66 h and 10.61 h for the test and reference formulation, respectively.",Bioequivalence study of rofecoxib tablets. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15497671/),h,10.66,269813,DB00533,Rofecoxib
,15497671,t(1/2 el),"The mean t(1/2 el) was 10.66 h and 10.61 h for the test and reference formulation, respectively.",Bioequivalence study of rofecoxib tablets. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15497671/),h,10.61,269814,DB00533,Rofecoxib
,15497671,MRT,"Mean MRT values for the test and reference tablets were 15.34 h and 15.33 h, respectively.",Bioequivalence study of rofecoxib tablets. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15497671/),h,15.34,269815,DB00533,Rofecoxib
,15497671,MRT,"Mean MRT values for the test and reference tablets were 15.34 h and 15.33 h, respectively.",Bioequivalence study of rofecoxib tablets. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15497671/),h,15.33,269816,DB00533,Rofecoxib
,15497671,MRT,"Mean MRT values for the test and reference tablets were 15.34 h and 15.33 h, respectively.",Bioequivalence study of rofecoxib tablets. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15497671/),h,15.34,269817,DB00533,Rofecoxib
,15497671,MRT,"Mean MRT values for the test and reference tablets were 15.34 h and 15.33 h, respectively.",Bioequivalence study of rofecoxib tablets. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15497671/),h,15.33,269818,DB00533,Rofecoxib
,12906745,oral bioavailability,"Mean oral bioavailability after single dose of rofecoxib (12.5, 25 or 50 mg) is 93% with t(max) varying widely between 2 and 9 h.","Rofecoxib: an update on physicochemical, pharmaceutical, pharmacodynamic and pharmacokinetic aspects. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12906745/),%,93,272101,DB00533,Rofecoxib
,12906745,t(max),"Mean oral bioavailability after single dose of rofecoxib (12.5, 25 or 50 mg) is 93% with t(max) varying widely between 2 and 9 h.","Rofecoxib: an update on physicochemical, pharmaceutical, pharmacodynamic and pharmacokinetic aspects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12906745/),h,2 and 9,272102,DB00533,Rofecoxib
,12906745,terminal half-life,Rofecoxib is eliminated predominantly by hepatic metabolism with a terminal half-life of approximately 17 h during steady state.,"Rofecoxib: an update on physicochemical, pharmaceutical, pharmacodynamic and pharmacokinetic aspects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12906745/),h,17,272103,DB00533,Rofecoxib
